Literature DB >> 35004964

Controlling cholesterol entry into mitochondria, a key step for hepatocarcinogenesis in non-alcoholic steatohepatitis-related hepatocellular carcinoma.

Guillermo Daniel Mazzolini1,2, Eda Kaya3,4, Ali Canbay3,4.   

Abstract

Entities:  

Year:  2021        PMID： 35004964      PMCID： PMC8683911          DOI： 10.21037/hbsn-21-406

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  15 in total

1.  Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.

Authors:  Judith Ertle; Alexander Dechêne; Jan-Peter Sowa; Volker Penndorf; Kerstin Herzer; Gernot Kaiser; Jörg F Schlaak; Guido Gerken; Wing-Kin Syn; Ali Canbay
Journal:  Int J Cancer       Date:  2011-03-14       Impact factor: 7.396

2.  Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.

Authors:  Lars P Bechmann; Peri Kocabayoglu; Jan-Peter Sowa; Svenja Sydor; Jan Best; Martin Schlattjan; Anja Beilfuss; Johannes Schmitt; Rebekka A Hannivoort; Alpaslan Kilicarslan; Christian Rust; Frieder Berr; Oliver Tschopp; Guido Gerken; Scott L Friedman; Andreas Geier; Ali Canbay
Journal:  Hepatology       Date:  2013-04       Impact factor: 17.425

3.  Efficacy and Safety of Statin for Hepatocellular Carcinoma Prevention Among Chronic Liver Disease Patients: A Systematic Review and Meta-analysis.

Authors:  Yu-Jun Wong; Tian-Yu Qiu; Gin-Kee Ng; Qishi Zheng; Eng Kiong Teo
Journal:  J Clin Gastroenterol       Date:  2021-08-01       Impact factor: 3.062

Review 4.  Steroidogenic acute regulatory protein (StAR), a novel mitochondrial cholesterol transporter.

Authors:  Walter L Miller
Journal:  Biochim Biophys Acta       Date:  2007-03-06

5.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

Review 6.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Robin Kate Kelley; Augusto Villanueva; Amit G Singal; Eli Pikarsky; Sasan Roayaie; Riccardo Lencioni; Kazuhiko Koike; Jessica Zucman-Rossi; Richard S Finn
Journal:  Nat Rev Dis Primers       Date:  2021-01-21       Impact factor: 52.329

7.  Bile Acid Receptors and Liver Cancer.

Authors:  Xichun Wang; Xianghui Fu; Carl Van Ness; Zhipeng Meng; Xiaoxiao Ma; Wendong Huang
Journal:  Curr Pathobiol Rep       Date:  2012-12-21

8.  STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.

Authors:  Laura Conde de la Rosa; Carmen Garcia-Ruiz; Carmen Vallejo; Anna Baulies; Susana Nuñez; Maria J Monte; Jose J G Marin; Lucia Baila-Rueda; Ana Cenarro; Fernando Civeira; Josep Fuster; Juan C Garcia-Valdecasas; Joana Ferrer; Michael Karin; Vicent Ribas; Jose C Fernandez-Checa
Journal:  J Hepatol       Date:  2021-01-27       Impact factor: 30.083

Review 9.  Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.

Authors:  Juan P Arab; Saul J Karpen; Paul A Dawson; Marco Arrese; Michael Trauner
Journal:  Hepatology       Date:  2016-08-04       Impact factor: 17.425

10.  Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet.

Authors:  Kouichi Miura; Hirohide Ohnishi; Naoki Morimoto; Shinichiro Minami; Mitsuaki Ishioka; Shunji Watanabe; Mamiko Tsukui; Yoshinari Takaoka; Hiroaki Nomoto; Norio Isoda; Hironori Yamamoto
Journal:  Cancer Sci       Date:  2019-01-09       Impact factor: 6.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.